liposomal amphotericin B

05/01/1993 - "Among 8 cases with proven invasive fungal infection, 6 were clinically cured, one had persistent fungi and one died after only 3 days of AmBisome therapy. "
12/01/2007 - "with L-AmB, can be a safe and effective strategy to reduce the frequency of invasive fungal infections in selected high-risk patients and to obtain significant cost savings for the hospital."
10/01/2006 - "We therefore evaluated a murine model of aerosol infection in two independent laboratories and found a high level of both intra- and interlaboratory reproducibility of survival, fungal burden over time, and the efficacy of liposomal amphotericin B."
01/01/2004 - "[Invasive infection by Aspergillus terreus treated successfully with liposomal amphotericin B]."
09/01/2000 - "Prolonged treatment with AmBisome and 5-flucytosine successfully eradicated the lesion, but the girl's antileukemic therapy was compromised due to the infection. "

10/01/2002 - "Liposomal amphotericin B is a new drug which is highly efficacious in the treatment of visceral leishmaniasis and produces minimal toxicity. "
05/01/1996 - "Liposomal amphotericin B is a promising new drug which is highly efficacious in the treatment of Indian kala-azar and produces minimal toxicity."
01/01/2009 - "Treatment with liposomal amphotericin B proved to be very effective in this severe case of visceral leishmaniasis."
01/01/1995 - "Recently complete remission of polyresistant visceral leishmaniasis was obtained by injection of liposomal amphotericin B. "
01/01/2012 - "For visceral leishmaniasis new formulations, therapeutic switching, in particular AmBisome, and the potential for combinations of established drugs have significantly improved the opportunities for the treatment in the Indian subcontinent, but not in East Africa. "

07/01/2005 - "Abelcet proved to be efficacious, but not curative, in the treatment of CNS aspergillosis and was equivalent overall to conventional AmB. "
12/01/2007 - "Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial."
12/01/2003 - "Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis."
12/01/1989 - "Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B."
08/01/2006 - "Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis."

01/01/2012 - "Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B."
11/01/2006 - "Monotherapy with high-dose liposomal amphotericin B successfully eradicated the mucormycosis. "
02/01/2014 - "We evaluated the efficacy of inhaled aerosolized L-AMB in murine invasive pulmonary mucormycosis. "
02/01/2014 - "The efficacy of inhaled L-AMB against mucormycosis has not been evaluated. "
02/01/2014 - "Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis."

12/01/2005 - "Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis."
02/01/1993 - "Liposomal amphotericin B was evaluated for toxicity, pharmacokinetic properties and therapeutic efficacy in invasive pulmonary aspergillosis in Sprague-Dawley rats. "
05/01/2013 - "Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis."
05/01/2002 - "In common with a proportion of patients with invasive pulmonary aspergillosis (IPA), the efficacy of AmBisome treatment regimens in our rat model remains suboptimal. "
03/01/1999 - "The in vivo efficacy of NS-718 in a rat model of invasive pulmonary aspergillosis was compared with those of D-AmB and L-AmB. "